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Metabolic outcomes in young children
with type 1 diabetes differ between treatment
centers: the Hvidoere Study in Young Children
2009*
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Objective: To investigate whether center differences in glycemic control are
present in prepubertal children <11 yr with type 1 diabetes mellitus.
Research Design and Methods: This cross-sectional study involved 18
pediatric centers worldwide. All children, <11 y with a diabetes duration
≥12 months were invited to participate. Case Record Forms included
information on clinical characteristics, insulin regimens, diabetic ketoacidosis
(DKA), severe hypoglycemia, language difficulties, and comorbidities.
Hemoglobin A1c (HbA1c) was measured centrally by liquid chromatography
(DCCT aligned, range: 4.4–6.3%; IFFC: 25–45 mmol/mol).
Results: A total of 1133 children participated (mean age: 8.0 ± 2.1 y; females:
47.5%, mean diabetes duration: 3.8 ± 2.1 y). HbA1c (overall mean: 8.0 ± 1.0%;
range: 7.3–8.9%) and severe hypoglycemia frequency (mean 21.7 events per
100 patient-years), but not DKA, differed significantly between centers
(p< 0.001 resp. p = 0.179). Language difficulties showed a negative
relationship with HbA1c (8.3 ± 1.2% vs. 8.0 ± 1.0%; p = 0.036). Frequency of
blood glucose monitoring demonstrated a significant but weak association
with HbA1c (r =−0.17; p< 0.0001). Although significant different HbA1c
levels were obtained with diverse insulin regimens (range: 7.3–8.5%;
p< 0.001), center differences remained after adjusting for insulin regimen
(p< 0.001). Differences between insulin regimens were no longer significant
after adjusting for center effect (p = 0.199).
Conclusions: Center differences in metabolic outcomes are present in children
<11 yr, irrespective of diabetes duration, age, or gender. The incidence of
severe hypoglycemia is lower than in adolescents despite achieving better
glycemic control. Insulin regimens show a significant relationship with HbA1c
but do not explain center differences. Each center’s effectiveness in using
specific treatment strategies remains the key factor for outcome.
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Optimizing metabolic control in association with
optimal quality of life is the major goal in childhood
type 1 diabetes mellitus (T1DM). Despite attempts
to improve metabolic outcomes through intensified
management, recent studies by the Hvidoere Study
Group (HSG) have shown persistent differences
between diabetes centers with respect to metabolic
control in adolescents in Europe, North America,
Japan, and Australia (1, 2). The study in 2005 provided
evidence that family dynamics and targets of control
may be of more significance than insulin regimens
in explaining center differences in adolescents despite
the fact that since the previous study there had
been a marked switch toward increased injection
frequency (3–5). Insulin regimens per se had only a
modest relationship with hemoglobin A1c (HbA1c),
with the exception of premixed insulins (resulting in
significantly higher HbA1c), and could not fully explain
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the observed center differences. Adolescence, however,
is a period characterized by major physical and
psychological changes, which are often more important
than changes in insulin or dietary regimens (6–8).
Intensifying treatment through increased injection
frequency or pumps may give more freedom to
adjust the treatment around peer-oriented lifestyle,
but whether this leads to improved metabolic outcome
depends on the ability to adhere to treatment and
education (8). In the younger children, the role of the
parents as caregivers is central and most influential
compared with the transitional phase toward self-
management in the early teenage years and afterward.
We, therefore, hypothesized that center differences
in glycemic control and acute complications might not
be so marked or might not be present in a young cohort
of children and that perhaps recent developments in
insulin regimens would have a more profound effect
on glycemic control compared with adolescents.
The purpose of this study was to identify the
relationship between current diabetes management and
center differences in metabolic outcomes in a large
cohort of younger children with T1DM.
Research design and methods
All children with T1DM, treated at the Hvidoere
Centers below 11 yr of age and with a diabetes
duration of at least 1 yr, were invited to participate
with informed parental consent. In centers with more
than 200 children aged <11 yr, only those seen by
the member of the Hvidoere Group were invited. For
all children, Clinical Record Forms (CRFs) including
questions on clinical characteristics, treatment,
and acute complications were collected. Detailed
descriptions of the insulin regimens, episodes of
severe hypoglycemia (seizures or loss of consciousness
in the past 3 months), diabetic ketoacidosis
(DKA requiring hospital admission within the past
12 months), and information on comorbidities (celiac
disease, hypothyroidism, and asthma) were obtained.
Questions on language difficulties with the parents
or the children were included to obtain some insight
into possible minority groups within the centers.
Reports of type 1 and 2 diabetes in first- and
second-degree relatives were obtained. A centralized
HbA1c measurement was performed by the TOSOH®
liquid chromatography (DCCT aligned, normal range:
4.4–6.3%; IFFC: 25–45 mmol/mmol).
Statistical analysis
Data were all double entered at a central administration
center. Ambiguous data on the CRF were resolved
by direct contact with participating centers. For
descriptive analysis, mean and SD were calculated for
continuous variables and percentages for categorical
variables. Rates of ketoacidosis and hypoglycemia
were estimated by the patient-years (PYs) method
and given as incident number of events per 100
PYs ± SE. All analyses were completed using spss
v19. Independent t-tests were used, when two groups
were compared. When Levene’s tests showed non-
equal variance between groups, the appropriate
corrected t and p values are quoted. Associations
between the different variables and HbA1c were
tested using analysis of variance (anova). Where the
dependent variables were not normally distributed,
Kruskal–Wallis test was utilized. For non-parametric
correlations between ordinal variables, Spearman’s
rho correlation coefficient was applied, whereas for
mixed-level data Kendall’s Tau was used and for
parametric data Pearson’s product moment coefficient
(with all results being significant at p< 0.001, unless
otherwise stated). The association between center
and HbA1c was tested by adding demographic and
medical characteristics as covariates, with categorical
covariates dummy coded.
Results
Of 1209 eligible children in 18 centers during the
recruitment period, 1133 (93.7%) children (47.4%
females; mean age: 8.0 ±2 yr; diabetes duration: 3.8
±2.1 yr) and their parents agreed to participate and
1107 (91.6%) provided a blood sample. Duration of
diabetes differed among the centers (center range:
2.9–4.3 yr; F = 1.907; p = 0.014), but age (F = 1.405;
p = 0.125) did not. Language difficulties were observed
in 4.5% of the families, varying significantly between
centers (center range: 0–11.5%; χ2 = 40.92; p = 0.001).
Comorbidities were present in 13.8% of the children
(center range: 1.9–27.5%) and differed significantly
across centers (χ2 = 48.79; p< 0.001) with celiac dis-
ease (5.8%), followed by hypothyroidism (1.7%) and
asthma (1.4%) as most frequent concomitant pathol-
ogy. A total of 12.8% of the children had one or more
first- or second-degree relatives with T1DM, with no
significant difference between the centers (χ2 = 14.24;
p = 0.649). A relative with type 2 diabetes (first or sec-
ond degree) was reported by 27.2% of the children, with
significant center difference (χ2 = 85.17; p< 0.001).
Metabolic control
The grand mean HbA1c was 8.0% ± 1.0 (n = 1107)
(64 mmol/mol; range: 4.7–13.6%) with 30.5% of
the children in good (<7.5%), 24.8% in acceptable
(7.5–8.0%), 31.6% in fair (8.1–9%), and 12% in
poor control (>9.0%). Glycemic control differed
significantly between the centers [anova (F = 22.24;
df = 17; p< 0.001) (Fig. 1A), with mean HbA1c levels
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varying between 7.3 ± 0.8% and 8.9 ± 1.1% (56 vs.
75 mmol/mol)]. There were no significant relationships
between age, gender, or diabetes duration and HbA1c
in this sample.
In 45 children (4% of the sample), 61 severe
hypoglycemic events were reported within the last
3 months, which is a frequency of 21.7 events/100 PYs.
In 26 children (2.3% of the sample), 42 DKA episodes
were reported for the last 12 months, representing
a frequency of 3.7 events/100 PYs. Mean HbA1c
of children with severe hypoglycemia did not differ
from those without severe hypoglycemia (7.9 ± 0.9 vs.
8.0 ± 1.0; t = 0.71; p = 0.47) nor did the mean HbA1c of
children with or without DKA (8.1 ± 0.7 vs. 8.0 ± 1.0;
t = 0.46; p = 0.65).
The incidence of severe hypoglycemic events differed
significantly between centers (χ2 = 44.66; p< 0.001),
whereas DKA frequency did not differ (χ2 = 22.15;
p = 0.179). Although significantly higher HbA1c levels
(t = 2.09; p = 0.036) were observed in individuals
or families with language problems (8.3 ± 1.1%;
67 mmol/mol vs. 7.9 ± 1.0%; 63 mmol/mol), it did
not explain the variation in glycemic control among
centers. Other cases of diabetes in the family were not
associated with metabolic outcomes in the children.
Insulin regimens
Different insulin regimens were used: CSII 32.8%,
basal bolus injections (BBIs) 16.9%, conventional twice
daily (CT) 36.5%, premixed insulins (CTpremix) 6.3%,
and twice daily variably free mixed with extra insulin
when deemed necessary (CTfreemix) 7.5%. Premixed
insulin consisting of a fixed percentage of short and
intermediate/long-acting insulin, whereas the freemix
insulin was defined as a variable combination of short
and long/intermediate-acting insulins, being mixed at
the time of injection, and given twice daily. anova
indicated significant differences in HbA1c between the
insulin regimens (F = 25.24; df = 4; p< 0.001), with
the highest HbA1c levels in the CTpremix group (8.5 ±
1.7%), CSII (7.8 ± 0.9%), BBI (8.0 ± 1.0%), and CT
(8.2 ± 1.0%). The lowest HbA1c levels were found in
the CTfreemix group (7.3 ± 0.5%).
No difference in DKA frequency was observed
across insulin regimens (χ2 = 4.36; p = 0.380) contrary
to the reported number of severe hypoglycemic events
(χ2 = 18.26; p = 0.001), which was highest in the
CTfreemix (42.4/100 PYs) and lowest in the CSII group
(5.4/100 PYs). No severe hypoglycemia was seen in
96% of all children.
Different insulin regimens used within the centers
are shown in Fig. 1B.
Mean insulin dose was 0.8 U ± 0.2/kg/d, with
considerable variation between centers (range: 0.68
U ± 0.2–0.93 U ± 0.3/kg/d) as well as between insulin
regimens. Children with CSII received the lowest (0.73
U ± 0.2/kg/d) and BBI the highest (0.87 U ± 0.3/kg/d)
daily insulin doses. Analyzing the ratio between
prandial and basal insulin (with exclusion of the
CTpremix), the ratio in CSII and BBI is higher than
in the CT regimens (0.55 vs. 0.32).
Frequency of blood glucose measurements (BGM
values, average over the past week) varied significantly
across centers (range: 2.5–8.3/d; F = 34.68; df = 17;
p< 0.001) and between insulin regimens with the
highest frequency in the CSII group (7.55 ± 2.25)
and the lowest in the CTpremix group (3.51 ± 1.76).
Frequency of BGM was higher in the younger children
<6 yr (6.7 ± 2.4 vs. 5.8 ± 2.1; t = 5.10; p< 0.0001) and
showed a significant but weak inverse relationship to
HbA1c r =−0.170; p < 0.0001), but this could not
explain the observed center differences in glycemic
control nor hypoglycemic events.
Comparison of metabolic outcome in adolescents
vs. younger children
When comparing the data obtained in adolescents in
2005, the centers achieving better metabolic control in
adolescents also show better outcome in the younger
population (r = 0.76; p = 0.01) (Fig. 2).
Discussion
This multicenter international study shows that both
HbA1c and frequency of severe hypoglycemia are
lower in a young cohort of children compared with
adolescents (1). Center differences in metabolic control
are already apparent in the young children and cannot
be clearly explained by any of the variables so far
tested. Current discussions concerning diabetes care
and long-term outcome include metabolic memory as
one of the predictors of outcome (9). This suggests that
one should strive for near normoglycemia starting at
the onset of diabetes. In this large cohort of young
children with T1DM, more than 50% had either
good or acceptable glycemic control (HbA1c < 8.0%)
compared with 41% of the under 11-yr olds in the
1998 study. Although nobody under 11-yr old in the
1998 study used either CSII or analog insulins, 32.8
and 100% used CSII and analog insulins, respectively,
in this study (5). Frequency of CSII differed from
around 15% in the adolescents (2005) to 32.8% in
these younger children (2), but 42.8% still receive
conventional twice daily insulin. Although the types
of insulin therapy show a significant relationship
with metabolic outcome, center differences persist
and are not explained by the treatment regimens,
comorbidities, language difficulties, or by frequency
of BGM. As in the adolescent study, it appears that
differences in the way that staff at a center apply
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Fig. 1. (A) Glycemic control in the participating centers ranked according to hemoglobin A1c (HbA1c) levels (*< grand mean for the
whole sample; ©= grand mean for the whole sample; and > grand mean for the whole sample). (B) Distribution of insulin regimens in the
participating centers ranked according to HbA1c levels.
a given insulin regimen seem to affect the mean
HbA1c achieved by the patients at each center, more
so than the insulin regimen used (4). In the 2005
study, team composition and services contributed
less to the differences in metabolic outcome among
centers than target setting and family dynamics;
data on the staffing structure and professional-
patient relationships have been collected and are
being analyzed. Conventional injection therapy with
twice daily premixed insulin in this young population
shows a significantly worse outcome than any of the
other regimens. This builds on our evidence from
previous studies showing poorer glycemic control using
premixed insulins in adolescents in 1998 and 2005 (1, 5).
Perhaps, this approach to insulin therapy in all children
should be reappraised especially with the available
evidence on metabolic memory (9). Not only long-term
complications but also neurocognitive deficits appear
to be influenced more by persistent hyperglycemia than
by hypoglycemia, as previously suggested (10–13).
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Fig. 2. Comparison of metabolic outcome of the centers
participating in both studies, 2005 and 2009 (r = 0.76; p = 0.01) (1).
On the other hand, children with major compliance
problems and significant family dysfunction may be
more comfortable with twice daily insulin regimens,
which in those situations give acceptable HbA1c
values with avoidance of DKA and hospitalization.
In the adolescent group, premix insulins may have
been introduced because of already established poor
metabolic control. In this study, optimal metabolic
control was achieved in a substantial proportion
of young children without excessive hypoglycemia.
Interestingly in this group, CSII was not associated
with the lowest HbA1c level, perhaps related to
greater freedom in lifestyle and eating behaviors
among these younger children. Some studies suggest
that insulin pump treatment reduces the risk of
hypoglycemia compared with conventional treatment
(14). Traditionally twice daily insulin regimens are
associated with higher rates of hypoglycemia, because
of the difficulty in balancing the intermediate-acting
insulins with food intake and their erratic absorption
characteristics especially during physical activity. The
beneficial effect of CSII in young children when started
early has been reported by Sulmont et al. (15).
The relatively high rate of severe hypoglycemic
events (21.7/100 PYs) in this study deserves some
discussion. Although significantly lower than in the
adolescents (27/100 PYs), only three children were
responsible for 11 events, leading to relatively high
incidence. In the remainder of the cohort, the frequency
of severe hypoglycemia was gratifyingly low (17.7/100
PYs), which supports the view that trying to obtain
good glycemic control in young children is not
necessarily associated with a high risk of hypoglycemia.
Whether the same results would have been obtained
with 12 months reporting of hypoglycemia (instead of
3 months) is uncertain, but retrospective questions
on hypoglycemia are fraught with difficulties (16, 17).
It should be noted that the incidence of severe
hypoglycemic events is lower, in all insulin regimens,
than in the intensive-therapy group of the DCCT, with
62 severe hypoglycemic episodes per 100 PYs (18).
In conclusion, in a large cohort of young children
with T1DM, center differences in metabolic control
are present. Individual HbA1c levels are related
to insulin regimens, but these regimens are not
significantly associated with center differences. The
success in which the staff at a specific center apply
a given insulin regimen seems to be associated
with the HbA1c achieved more than the insulin
regimen itself. The incidence of severe hypoglycemia
in this young cohort was lower than in adolescence
despite achieving a significantly lower HbA1c. Further
analysis of quality of life, team composition, team
relationships, and services is currently being conducted
to evaluate whether these indicators are associated with
metabolic control. Finally, examining the education
and proficiency of parents in day-to-day fine-tuning of
insulin adjustments might be a future step for the HSG
to explore center differences.
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